The awardees will each receive a $50,000 grant to support an independent research project focused on advancing melanoma prevention or detection.

The Melanoma Research Alliance (MRA) has announced its 2023 Dermatology Fellowship Award recipients. 

The awardees will each receive a $50,000 grant to support an independent research project focused on advancing melanoma prevention or detection. Along with critical financial support, the fellows will have the opportunity to collaborate with MRA's extensive network of melanoma experts and researchers, and career development and networking opportunities.

The 2023 MRA Dermatology Fellowship Awardees are:

EN2 and HOXD13 are Two Novel Melanoma-Specific Transcription Factors
Pietro Berico Ph.D., New York University Grossman School of Medicine 

The Role of APOE Isoforms in the Hereditary Basis of Rare Melanomas
Neil Neumann M.D., Ph.D., The Rockefeller University 

Epigenetics and Acral Melanoma Prognostic Model for Skin of Color Patients
Simon F. Roy M.D., Yale University 

Micronuclear Rupture and DNA Damage in Primary Cutaneous Melanoma Prognosis
Xiao Zhang Ph.D., The University of California, Los Angeles

The MRA Dermatology Fellowship program, underwritten by Denise and Michael Kellen, and the Anna-Maria and Stephen Kellen Foundation, is part of a broader effort by MRA to champion research focused on prevention and early detection of melanoma and other skin cancers. Over the program's five-year history, it has supported a broad range of research projects across the United States, including telemedicine, artificial intelligence, and non-invasive imaging, detection of melanoma in People of Color, among others.

"We are making transformative advances in the treatment of advanced melanoma," says MRA Chief Science Officer Joan Levy, PhD, in a news release. "However, with over 100,000 new cases of invasive melanoma expected this year, it's clear we need to continue to advance precision prevention and the early detection of disease, when melanoma is most curable. We are proud of our newest awardees and welcome them into the greater MRA community of patients, researchers and advocates."